o2h Ventures
Robert Boyle is an experienced leader in the pharmaceutical and biotechnology sectors, currently serving as the CEO of Sentinel Oncology since April 2005. In addition to this role, Boyle is a Board Member at Oxford Drug Design and a Venture Partner at o2h Ventures Limited, both positions held since 2019. Prior experience includes serving as Director at NeoPhore Ltd from October 2017 to January 2019, Senior Research Associate at Astex Pharmaceuticals from October 2003 to April 2005, and Sr Scientist II at Millennium Pharmaceuticals from 2000 to 2003. Earlier in the career, Boyle was a Group Leader at Cambridge Discovery Chemistry from June 1997 to September 2000 and worked as an Associate Scientist at Pfizer from August 1993 to June 1997.
This person is not in any teams
o2h Ventures
o2h Ventures is an established fund manager based in the heart of the biotech community in central Cambridge. We are a specialist fund that only invests in biotech therapeutics and the intersection between biotechnology and AI/ML. This fund is pivotal in developing the biotech ecosystem in the o2h Group but also has invested into 28 early-stage biotech companies in Great Britain. We have two specialist tax-efficient funds open for investment - 1. The o2h human health SEIS Fund 2. The o2h human health EIS knowledge-intensive Fund Disclaimer: Please refer to the relevant fund’s full risk warnings contained in their Information Memorandums. Your capital is at risk. Investing in early-stage businesses involves risks, including illiquidity, lack of dividends, loss of investment and dilution, and it should be done only as part of a diversified portfolio. o2h Ventures’ funds are targeted exclusively at sophisticated or high-net-worth investors who understand these risks and make their own investment decisions. Tax relief depends on an individual’s circumstances and may change in the future. In addition, the availability of tax relief depends on the company invested in maintaining its qualifying status. Past performance is not a reliable indicator of future performance. You should not rely on any past performance as a guarantee of future investment performance. o2h Ventures Ltd is a limited company registered in England and Wales under number 11397838 and is authorised and regulated by the Financial Conduct Authority (FRN 812245). The registered office and principal place of business is Hauxton House, Mill Scitech Park, Mill Lane, Hauxton, Cambridge, CB22 5HX, United Kingdom.